- « Previous
- Clinical Pharmacology
- Next »
Ultram ER
Clinical Pharmacology
Ultram ER
In one 12-week randomized, double-blind, placebo-controlled flexible-dosing trial of ULTRAM ER in patients with osteoarthritis of the knee, an average daily ULTRAM ER dose of approximately 270 mg/day demonstrated a statistically significant decrease in the mean VAS score, and a statistically significant difference in the responder rate, based on the percent change from baseline in the VAS score, measured at 1, 2, 4, 8, and 12 weeks, between patients receiving ULTRAM ER and placebo (see Figure 4).
Figure 4.
 |
ULTRAM ER Study 015 Arthritis Pain Intensity VAS Responder Analysis Patients Achieving Various Levels of Response Threshold
Generic Name: Tramadol HCl Extended-Release
- « Previous
- Clinical Pharmacology
- Next »
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Health Extras
Touch Your Way to Health
Hear from experts on different types of therapeutic massage, how to find a good therapist, and when you should avoid altogether. See more WebMD Videos »
Ultram ER
Related Drugs
Health Resources
Updated & New
RxList does not provide medical advice, diagnosis or treatment.